Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Urban

Showing results (131-140 of 134) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 134 results.
The Lancet. Infectious Diseases|September 16, 2022
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trialHeiner Wedemeyer, Katrin Schöneweis, Pavel Bogomolov, et al.
Journal of Hepatology|July 17, 2023
Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized miceFlorian A Lempp, Tassilo Volz, Elisabetta Cameroni, et al.
The Journal of General Virology|May 17, 2024
Highlights from the 2023 International Meeting on the Molecular Biology of Hepatitis B virus, Lena Allweiss, Chari Cohen, et al.
Journal of Hepatology|February 8, 2022
Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicityAhmed Ghallab, Reham Hassan, Ute Hofmann, et al.
Pageof 14

Showing results (131-140 of 134) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 134 results.
The Lancet. Infectious Diseases|September 16, 2022
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trialHeiner Wedemeyer, Katrin Schöneweis, Pavel Bogomolov, et al.
Journal of Hepatology|July 17, 2023
Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized miceFlorian A Lempp, Tassilo Volz, Elisabetta Cameroni, et al.
The Journal of General Virology|May 17, 2024
Highlights from the 2023 International Meeting on the Molecular Biology of Hepatitis B virus, Lena Allweiss, Chari Cohen, et al.
Journal of Hepatology|February 8, 2022
Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicityAhmed Ghallab, Reham Hassan, Ute Hofmann, et al.
Pageof 14